Read How Analysts Reacted To Cintas's Q3 Results

March 24, 2022 12:44 PM | 1 min read | Make a Comment

Cintas Corp's CTAS price target was raised to $493 from $460 by Goldman Sachs analyst George Tong while maintaining the Buy rating on the shares.
Tong predicts continued strength from the healthcare sector that is increasingly adopting uniform rental programs at Cintas post-COVID due to cost and hygiene benefits.
Related: Cintas' Q3 Results Beat Estimates, Clocks 10% Revenue Growth
The analyst notes the company is well-positioned to handle higher input costs with pricing power and technology-enabled efficiencies.
Morgan Stanley lowered its price target on CTAS to $389 (a downside of 2.8%) from $416 while maintaining an Equal-Weight rating on the shares.
Price Action: CTAS shares are trading lower by 0.26% at $400.31 on the last check Thursday.